美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Direxion Daily Biotech Top 5 Bull 2X ETF

38.36

-0.5386-1.38%

成交量：7,280

成交額：28.42萬

市值：287.70萬

市盈率：- -

高：39.06

開：39.06

低：38.36

收：38.90

52周最高：45.88

52周最低：25.71

股本：7.50萬

流通股本：7.50萬

量比：0.49

換手率：9.71%

股息：0.62

股息率：1.62%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

安進高管重申：2026年資本支出預計約26億美元，用於擴大產能，含Maritide上市準備

安進高管：Q2資本支出達5億美元，聚焦全美製造基地投資——電話會議紀要

安進高管在電話會議上表示，第二季度資本支出達5億美元，主要受美國各地生產基地投資推動。

吉利德高管在電話會議中宣佈：全年HIV業務增長預期上調至9%-10%，此前指引為8%

吉利德高管：距FDA PDUFA日期僅剩五個月，Anito-Cel細胞療法上市籌備工作已全面啓動

吉利德科學第二季度調整後每股收益-6.75美元，高於IBES預估-7.24美元

安進(AMGN)股票8月4日收盤上漲3.03%：關鍵驅動因素揭曉

TradingKey中文

吉利德科學：季度調整後每股虧損6.75美元，反映近期收購帶來的每股9.08美元知識產權研發及税務支出

安進第二季度銷售額增長9%，利潤超出華爾街預期

吉利德第二季度銷售額增長8%，超出華爾街預期

前瞻：安進股價在財報公布前走高

Vertex 擴大領導團隊，為下一階段增長注入強勁動力

重點關注個股：Palantir、SpaceX、滙豐控股

非阿片止痛藥新鋭Latigo(LTGO.US)IPO擬最高募資2.88億美元，Nav1.8抑制劑劍指福泰製藥(VRTX.US)百億市場

福泰製藥重申2026年全年指引：GAAP與非GAAP研發、AI研發及銷售管理費用預期不變

福泰製藥：基於現行關税法規，2026年指引中關税成本影響依然微乎其微

Vertex憑藉囊性纖維化藥物的強勁表現上調年度營收預期

加州最高法院在「創新義務」案中裁定吉利德勝訴

加州最高法院裁定吉利德科學勝訴，HIV藥物「創新責任」案塵埃落定

安進7月遭網絡攻擊部分患者信息被盜

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/TBXU/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TBXU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TBXU\",,,,,undefined,":{"symbol":"TBXU","market":"US","secType":"STK","nameCN":"Direxion Daily Biotech Top 5 Bull 2X ETF","latestPrice":38.3601,"timestamp":1789156800000,"preClose":38.8987,"halted":0,"volume":7280,"delay":0,"changeRate":-0.01384622108193835,"floatShares":75001,"shares":75001,"eps":0,"marketStatus":"盤前交易","change":-0.5386,"latestTime":"09-14 08:58:06 EDT","open":39.06,"high":39.06,"low":38.3601,"amount":284204,"amplitude":0.017993,"askPrice":61.37,"askSize":200,"bidPrice":17.55,"bidSize":100,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789392600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":38.3601,"sharesOutstanding":100001,"nav":38.336,"aum":2875239.83,"dividendRate":0.01621,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.5301,"preClose":38.3601,"latestTime":"16:10 EDT","volume":6,"amount":230.1604,"timestamp":1789157404900,"change":0.17,"changeRate":0.004432,"amplitude":0},"volumeRatio":0.4910292679310407},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TBXU\",,,,,undefined,":{"symbol":"TBXU","floatShares":75001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4910292679310407,"shares":75001,"dividePrice":0.6218,"high":39.06,"amplitude":0.017993,"preClose":38.8987,"low":38.3601,"week52Low":25.71,"pbRate":"--","week52High":45.88,"institutionHeld":0,"latestPrice":38.3601,"committee":-0.333333,"eps":0,"divideRate":0.01621,"volume":7280,"delay":0,"ttmEps":0,"open":39.06,"prevYearClose":31.065,"prevWeekClose":38.3601,"prevMonthClose":42.9245,"prevQuarterClose":32.1223,"fiveDayClose":45.76,"twentyDayClose":38.3309,"sixtyDayClose":29.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TBXU\",params:#limit:5,,,undefined,":[{"date":"2026-06-23","symbol":"TBXU","amount":0.11101,"announcedDate":"2026-06-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-23","defaultRemindTime":1782221400000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-23","currency":"USD","dateTimestamp":1782187200000,"payDate":"2026-06-30"},{"date":"2026-03-24","symbol":"TBXU","amount":0.09893,"announcedDate":"2026-03-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-24","defaultRemindTime":1774359000000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-24","currency":"USD","dateTimestamp":1774324800000,"payDate":"2026-03-31"},{"date":"2025-12-23","symbol":"TBXU","amount":0.10111,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-31"},{"date":"2025-12-10","symbol":"TBXU","amount":0.31143,"announcedDate":"2025-12-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-10","defaultRemindTime":1765377000000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-17","payableDate":"2025-12-10","currency":"USD","dateTimestamp":1765342800000,"payDate":"2025-12-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TBXU\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-10","recordDate":"2025-12-10","paymentDate":"2025-12-17","value":0.31143,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-31","value":0.10111,"currency":"USD"},{"executeDate":"2026-03-24","recordDate":"2026-03-24","paymentDate":"2026-03-31","value":0.09893,"currency":"USD"},{"executeDate":"2026-06-23","recordDate":"2026-06-23","paymentDate":"2026-06-30","value":0.11101,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TBXU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TBXU\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1191538261","title":"安進高管重申：2026年資本支出預計約26億美元，用於擴大產能，含Maritide上市準備","url":"https://stock-news.laohu8.com/highlight/detail?id=1191538261","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191538261?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:01","pubTimestamp":1785877307,"startTime":"0","endTime":"0","summary":"安进高管最新表态，公司将继续维持2026年资本支出约26亿美元的预期。这笔资金的核心用途，正是为了扩大制造产能——其中，Maritide的上市准备工作尤为关键。\n26亿美元，一个庞大的数字，却承载着安进对未来市场的信心与布局。产能扩张，尤其是为Maritide的上市铺路，成为了这笔巨额支出的重中之重。这不仅仅是一次简单的投资，更是对战略产品线的全力押注。\n高管在发言中强调，该预期反映了公司对生产能力持续优化的坚定承诺。从长远来看，扩大制造规模不仅是为了满足现有产品的需求，更是为了确保Maritide等关键新药能够顺利推向市场。这一举措，无疑将为公司在竞争激烈的生物制药领域构筑更坚实的护城河。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","IBBQ","IE0009355771.USD","BK4599","IE00B2B36J28.USD","PJP","IE00B4R5TH58.HKD","LU1057294990.SGD","LU0122379950.USD","BK4533","BBH","LU1023059063.AUD","LU2112291526.USD","BK4534","LU2468319806.SGD","BK4139","LU2242646821.SGD","LU1983299246.USD","AMGN","LU2089984988.USD","LU0320765992.SGD","IBB","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU1571399168.USD","BK4581","PBE","TBXU","BK4566","BIB","BK4585","LU2242652126.USD","LU0868494617.USD","LU0058720904.USD","IE0002141913.USD","SG9999001440.SGD","LU1061106388.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128189819","title":"安進高管：Q2資本支出達5億美元，聚焦全美製造基地投資——電話會議紀要","url":"https://stock-news.laohu8.com/highlight/detail?id=1128189819","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128189819?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:01","pubTimestamp":1785877299,"startTime":"0","endTime":"0","summary":"安进（Amgen）公司高管在电话会议中透露，第二季度资本支出高达5亿美元。这笔巨额投入的核心驱动力，正是该公司在全美多个制造基地进行的战略布局。投资浪潮席卷了美国的各个生产设施，从而推动了整体资本开支的显著增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0122379950.USD","TBXU","PJP","SG9999001440.SGD","IBB","LU0289739699.SGD","IE00B2B36J28.USD","BK4585","BIB","BK4533","BK4534","LU0320765992.SGD","LU2242646821.SGD","BBH","AMGN","LU0058720904.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU1023059063.AUD","PBE","LU1983299246.USD","BK4139","LU2468319806.SGD","LU1061106388.HKD","BK4566","IE00B4R5TH58.HKD","LU2242652126.USD","BK4581","IE0002141913.USD","LU1571399168.USD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU0868494617.USD","IBBQ","LU1057294990.SGD","LU2112291526.USD","BK4599","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657562205","title":"安進高管在電話會議上表示，第二季度資本支出達5億美元，主要受美國各地生產基地投資推動。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657562205","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657562205?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:59","pubTimestamp":1785877188,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","LU2112291526.USD","LU0289739699.SGD","LU2089984988.USD","PBE","PJP","AMGN","BK4534","LU1061106388.HKD","BK4599","BIB","BK4533","LU0109394709.USD","LU0320765992.SGD","FXR","LU1057294990.SGD","BBH","LU1571399168.USD","TBXU","LU1023059063.AUD","LU0868494617.USD","LU0889565916.HKD","BK4588","IBB","DUSL","LU2468319806.SGD","LU0122379950.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","LU1983299246.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4139","IE00B2B36J28.USD","IE0009355771.USD","SG9999001440.SGD","BK4585","BK4566","BK4581","LU2242652126.USD","LU2242646821.SGD","IE0002141913.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135051692","title":"吉利德高管在電話會議中宣佈：全年HIV業務增長預期上調至9%-10%，此前指引為8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135051692","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135051692?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:42","pubTimestamp":1785876147,"startTime":"0","endTime":"0","summary":"吉利德（Gilead Sciences）高管在电话会议上透露，公司已将全年HIV业务增长预期上调至9%至10%的区间。这一调整较此前8%的增长指引显著提升，展现了公司对该业务领域强劲势头的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU1061106388.HKD","IE0002270589.USD","LU0320765992.SGD","LU1037948541.HKD","LU1674673691.USD","LU1934455277.USD","IBB","IE00B7SZLL34.SGD","LU0109394709.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","BK4532","LU0965509283.SGD","LU1066053197.SGD","BK4139","LU2112291526.USD","LU1934455863.HKD","IE00B3T34201.USD","LU1057294990.SGD","BK4566","LU0965509010.AUD","LU0889565916.HKD","LU1674673428.USD","LU1571399168.USD","IE00B19Z3581.USD","LU2089984988.USD","LU1934455194.USD","LU2468319806.SGD","BIB","BK4550","LU0114720955.EUR","BK4585","LU0289739699.SGD","LU2324357040.USD","IE00BKVL7J92.USD","LU0861579265.USD","LU1037948897.HKD","TBXU","IE00B19Z3B42.SGD","LU0965508806.USD","LU1778281490.HKD","LU1430594728.SGD","SG9999015952.SGD","SG9999015978.USD","SG9999015986.USD","LU0823416689.USD","BK4578","LU0122379950.USD","LU1023059063.AUD","SG9999015945.SGD","TMED","LU0882574055.USD","BK4588","BMED","GILD","IBBQ","LU0965509101.SGD","LU1839511570.USD","MEDI","LU0234570918.USD","LU2087621335.USD","IE00BSNM7G36.USD","BBH","BK4583","BK4568","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145483121","title":"吉利德高管：距FDA PDUFA日期僅剩五個月，Anito-Cel細胞療法上市籌備工作已全面啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1145483121","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145483121?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:42","pubTimestamp":1785876146,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）高管透露，针对其重磅细胞疗法Anito-Cel的上市准备工作已全面铺开，目前距离美国食品药品监督管理局（FDA）设定的PDUFA目标日期仅剩五个月时间。这一消息源自公司近期召开的电话会议。\n在会议中，高管进一步强调，公司正紧锣密鼓地推进各项筹备事项，以确保一旦获批，该疗法能够迅速进入市场。Anito-Cel作为一种前沿的细胞治疗产品，被视为吉利德在肿瘤学领域布局的关键一环。随着最终审批日期的临近，市场对这款疗法的商业化前景给予高度关注，而吉利德方面则展现出对既定时间表与执行能力的充分信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","SG9999015978.USD","LU1066051498.USD","LU1934455194.USD","LU1061106388.HKD","IE00BZ1G4Q59.USD","LU1674673428.USD","TMED","SG9999015952.SGD","IBB","LU1023059063.AUD","LU0320765992.SGD","BK4583","BK4588","LU2087621335.USD","BK4585","IBBQ","LU0965509010.AUD","LU1778281490.HKD","LU0965508806.USD","LU1585245621.USD","BK4578","BK4550","IE00B19Z3581.USD","LU0823416689.USD","LU0882574055.USD","LU2089984988.USD","TBXU","LU0289739699.SGD","LU0861579265.USD","LU0965509283.SGD","IE00B7SZLL34.SGD","LU1037948541.HKD","LU1571399168.USD","LU1674673691.USD","SG9999015986.USD","IE0002270589.USD","LU0109394709.USD","LU1430594728.SGD","BK4568","LU0889565916.HKD","LU1934455277.USD","BBH","BMED","LU2112291526.USD","BIB","LU0058720904.USD","LU1057294990.SGD","IE00B3T34201.USD","MEDI","LU2324357040.USD","LU0114720955.EUR","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0234570918.USD","LU0965509101.SGD","LU1037948897.HKD","IE00BSNM7G36.USD","LU1839511570.USD","LU2468319806.SGD","LU1066053197.SGD","LU1934455863.HKD","BK4532","GILD","SG9999015945.SGD","BK4139","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163992816","title":"吉利德科學第二季度調整後每股收益-6.75美元，高於IBES預估-7.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163992816","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163992816?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:17","pubTimestamp":1785874678,"startTime":"0","endTime":"0","summary":"8月4日，吉利德科学（Gilead Sciences）公布第二季度产品销售额达76.27亿美元。第二季度调整后每股收益为-6.75美元，优于IBES预估的-7.24美元。","market":"us","thumbnail":"https://static.tigerbbs.com/9e7ba54e8539d48dd315975babea7852","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9e7ba54e8539d48dd315975babea7852"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965508806.USD","LU1934455194.USD","BK4550","SG9999015952.SGD","LU2468319806.SGD","LU0122379950.USD","SG9999015945.SGD","IBB","LU1023059063.AUD","LU1778281490.HKD","LU0965509101.SGD","LU2324357040.USD","LU0109394709.USD","SG9999015978.USD","IE00B7SZLL34.SGD","LU0861579265.USD","LU1057294990.SGD","LU1674673428.USD","SG9999015986.USD","BK4568","LU0965509010.AUD","BK4583","IBBQ","IE00B3T34201.USD","BK4566","BK4588","GILD","LU0114720955.EUR","LU1066053197.SGD","LU1839511570.USD","BIB","LU1571399168.USD","LU1934455863.HKD","LU0889565916.HKD","LU0320765992.SGD","BK4578","BMED","LU1061106388.HKD","LU0234570918.USD","LU1430594728.SGD","LU0058720904.USD","LU2112291526.USD","BK4585","IE00BSNM7G36.USD","TBXU","LU0289739699.SGD","LU0882574055.USD","LU1037948897.HKD","BBH","LU1037948541.HKD","IE00BZ1G4Q59.USD","LU1585245621.USD","MEDI","LU1934455277.USD","LU1674673691.USD","TMED","LU2089984988.USD","IE00B19Z3B42.SGD","BK4532","IE00B19Z3581.USD","IE0002270589.USD","LU0823416689.USD","LU0965509283.SGD","LU2087621335.USD","IE00BKVL7J92.USD","LU1066051498.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657627865","title":"安進(AMGN)股票8月4日收盤上漲3.03%：關鍵驅動因素揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2657627865","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657627865?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:16","pubTimestamp":1785874591,"startTime":"0","endTime":"0","summary":"• 安进公布的第二季度业绩超出了市场对营收和每股收益的共识预期。\n• 一款代谢健康候选药物的积极中期临床数据推动了其股价上涨。\n• 全年营收达到367.5亿美元，该公司的净利润排名位列第十。","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262074405-market-movers-amgn-20260804","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU2089984988.USD","LU2242646821.SGD","LU0058720904.USD","BK4139","IE0009355771.USD","LU1057294990.SGD","IBB","LU0122379950.USD","LU0889565916.HKD","AMGN","LU2112291526.USD","IE00BJT1NW94.SGD","PBE","LU0289739699.SGD","LU1983299246.USD","BK4581","BK4599","IE00B4R5TH58.HKD","LU0868494617.USD","IBBQ","LU2242652126.USD","LU1061106388.HKD","BK4588","IE00BJJMRZ35.SGD","BBH","IE0002141913.USD","TBXU","BK4585","LU1571399168.USD","IE00BFTCPJ56.SGD","BK4533","IE00B2B36J28.USD","PJP","LU2468319806.SGD","SG9999001440.SGD","LU0320765992.SGD","BK4534","BIB","LU1023059063.AUD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108344321","title":"吉利德科學：季度調整後每股虧損6.75美元，反映近期收購帶來的每股9.08美元知識產權研發及税務支出","url":"https://stock-news.laohu8.com/highlight/detail?id=1108344321","media":"美股速递","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108344321?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:04","pubTimestamp":1785873878,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）最新季度业绩揭晓。数据显示，公司调整后每股收益为-6.75美元。这一数字背后，折射出近期收购活动所产生的重大财务影响——具体而言，每股9.08美元的知识产权研发成本与税务费用被计入。这些支出，均与公司近期完成的收购交易紧密相关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU1066053197.SGD","LU1066051498.USD","LU0965509101.SGD","LU2324357040.USD","BK4550","LU0114720955.EUR","IBB","LU0289739699.SGD","TBXU","LU2089984988.USD","IBBQ","BBH","IE00BSNM7G36.USD","LU1037948897.HKD","LU1839511570.USD","BK4578","BK4588","LU0889565916.HKD","LU1674673691.USD","LU1674673428.USD","BK4566","LU0823416689.USD","LU1571399168.USD","SG9999015952.SGD","IE00B7SZLL34.SGD","LU1057294990.SGD","LU1061106388.HKD","MEDI","IE00BZ1G4Q59.USD","SG9999015945.SGD","BMED","GILD","LU1934455194.USD","LU1934455863.HKD","IE0002270589.USD","LU1778281490.HKD","LU1934455277.USD","LU2112291526.USD","IE00B3T34201.USD","TMED","BK4583","IE00B19Z3581.USD","LU0109394709.USD","LU2087621335.USD","LU0234570918.USD","LU1430594728.SGD","BIB","LU0965509283.SGD","LU0122379950.USD","BK4568","LU0861579265.USD","LU0965509010.AUD","LU1023059063.AUD","LU1037948541.HKD","BK4585","LU1585245621.USD","SG9999015978.USD","SG9999015986.USD","LU0965508806.USD","BK4532","LU2468319806.SGD","BK4139","IE00B19Z3B42.SGD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657569101","title":"安進第二季度銷售額增長9%，利潤超出華爾街預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2657569101","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657569101?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:04","pubTimestamp":1785873843,"startTime":"0","endTime":"0","summary":"安进第二季度销售额增长9%，利润超出华尔街预期经调整的每股收益为6.29美元，超出分析师预期上调全年营收和利润预期安进公司停止开发第二款实验性减肥药AMG 513Deena Beasley路透8月4日-安进公司周二公布，受降胆固醇药物Repatha、骨质疏松药物Evenity以及罕见病药物需求推动，第二季度销售额增长9%。季度营收同比增长10%，达到101亿美元，超过了华尔街94.2亿美元的平均预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL4T4411XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","AMGN","BK4534","IE00BJT1NW94.SGD","LU1061106388.HKD","PBE","IBBQ","LU1983299246.USD","BK4566","BK4588","IE0002141913.USD","BBH","LU2089984988.USD","LU0058720904.USD","04332","LU2242652126.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU0289739699.SGD","BIB","IE00B2B36J28.USD","LU0889565916.HKD","PJP","TBXU","BK4599","IE00BJJMRZ35.SGD","LU2242646821.SGD","BK4581","BK4585","IE00B4R5TH58.HKD","IBB","LU0109394709.USD","LU0868494617.USD","LU0320765992.SGD","LU2112291526.USD","IE0009355771.USD","BK4533","LU1571399168.USD","BK4139","SG9999001440.SGD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657820569","title":"吉利德第二季度銷售額增長8%，超出華爾街預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2657820569","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657820569?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873759,"startTime":"0","endTime":"0","summary":"据LSEG数据显示，该公司总营收增长10%至78亿美元，超出华尔街预期的74亿美元。第二季度，吉利德公布经调整后每股亏损为6.75美元，而华尔街分析师平均预期为7.24美元。另一款较早上市的艾滋病口服药Descovy的季度销售额猛增48%，达到9.67亿美元，增幅超出预期。吉利德表示，其肝病产品组合的销售额增长10%，达到8.77亿美元，而细胞疗法产品的销售额则下降14%，至4.17亿美元，这反映出市场竞争加剧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL4T4411XD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","LU0114720955.EUR","BK4566","SG9999015978.USD","LU0320765992.SGD","LU1674673428.USD","LU2468319806.SGD","BMED","GILD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4585","IBBQ","LU1934455277.USD","LU1066051498.USD","IE00B3T34201.USD","BK4568","IBB","LU0965508806.USD","SG9999015952.SGD","BK4588","SG9999015945.SGD","LU2324357040.USD","BK4583","IE00B19Z3581.USD","LU0889565916.HKD","LU0109394709.USD","BBH","LU0289739699.SGD","LU1061106388.HKD","IE00BZ1G4Q59.USD","LU0058720904.USD","BIB","LU2089984988.USD","LU1571399168.USD","LU0823416689.USD","LU0882574055.USD","LU0965509283.SGD","LU0965509101.SGD","SG9999015986.USD","TMED","LU2112291526.USD","LU0234570918.USD","BK4139","LU1585245621.USD","LU1778281490.HKD","TBXU","LU1037948897.HKD","IE00BSNM7G36.USD","LU0965509010.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657568090","title":"前瞻：安進股價在財報公布前走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568090","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657568090?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 01:30","pubTimestamp":1785864614,"startTime":"0","endTime":"0","summary":"BUZZ-前瞻：安进股价在财报公布前走高8月4日-** 安进AMGN.O股价周二上涨2.2%，该公司将于收盘后公布季度财报，投资者正密切关注其试验性减肥药的最新进展** 据伦敦证券交易所集团（LSEG）预测，这家生物技术公司预计将公布季度营收增长3%至94.2亿美元，而调整后每股收益则可能从6.02美元降至5.62美元** 在过去8个季度中，AMGN有7个季度达到了或超过了每股收益预期，最近一次未","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL4S4411RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","BK4581","PJP","BK4599","LU1571399168.USD","TBXU","IE0002141913.USD","BBH","LU0889565916.HKD","LU2468319806.SGD","IBB","BK4585","PBE","LU0868494617.USD","SG9999001440.SGD","LU1983299246.USD","LU1061106388.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4534","LU2242652126.USD","LU2112291526.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","BK4139","LU1023059063.AUD","IE00BJT1NW94.SGD","IBBQ","LU2089984988.USD","BK4588","AMGN","LU0320765992.SGD","BIB","BK4566","LU0122379950.USD","BK4533","LU0058720904.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117517951","title":"Vertex 擴大領導團隊，為下一階段增長注入強勁動力","url":"https://stock-news.laohu8.com/highlight/detail?id=1117517951","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117517951?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 20:02","pubTimestamp":1785844955,"startTime":"0","endTime":"0","summary":"宾夕法尼亚州普鲁士王，2026年8月4日——全球间接税与合规领域的“决策到防御”先锋，Vertex Inc.，今日宣布其领导团队迎来三位新成员，旨在为公司下一阶段的蓬勃发展提供坚实支撑。他们的加入，将通过对人才、区域运营及技术创新的领导力扩展，进一步强化 Vertex 的全球增长战略。在 Vertex，她将负责全球人才与企业文化战略，构建起推动业务规模化发展所需的人才储备和组织能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","IE00B19Z9P08.USD","LU2417539215.USD","LU2456880835.USD","TM","IE00B894F039.SGD","TBXU","SGXZ57979304.SGD","LU0889565916.HKD","GNMX","LU1674673428.USD","BK4084","LU1674673691.USD","IE00B4R5TH58.HKD","IE00B19Z3B42.SGD","BBH","BK4588","BK4533","LU1585245621.USD","IE0002270589.USD","SG9999001176.SGD","LU0058720904.USD","SG9999013999.USD","VRTX","PW","LU0289739699.SGD","LU0109394709.USD","LU2237438978.USD","LU0061475181.USD","IE00B19Z3581.USD","LU1815336091.USD","IE0002141913.USD","LU1778281490.HKD","LU2236285917.USD","LU2462157665.USD","LU2362541513.USD","BK4120","SG9999001176.USD","IE00BJT1NW94.SGD","LU0079474960.USD","LU1093756168.USD","03160","LU1035775433.USD","BK4532","TISI","IE00BJJMRZ35.SGD","BK4099","LU0417517546.SGD","BK4555","IE0009355771.USD","LU0320765992.SGD","LU1430594728.SGD","LU0234570918.USD","LU2362541273.HKD","LU0757428866.USD","LU2089984988.USD","BIB","IE00B19Z9Z06.USD","LU0566484027.USD","IBB","PBE","LU0256863811.USD","BK4567","LU2324357040.USD","LU1093756325.SGD","IE00BZ9MQY76.HKD","BK4023","VERX","BK4139","LU1559883803.SGD","BK4585","BK4604","BK4234","LU2468319806.SGD","IE00B2B36J28.USD","LU2362540622.SGD","LU0823416689.USD","LU1069344957.HKD","IBBQ","IE00BFTCPJ56.SGD","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103561229","title":"重點關注個股：Palantir、SpaceX、滙豐控股","url":"https://stock-news.laohu8.com/highlight/detail?id=1103561229","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103561229?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 17:28","pubTimestamp":1785835721,"startTime":"0","endTime":"0","summary":"**Palantir Technologies **：这家软件公司昨日盘后公布了强劲的财报，业绩表现亮眼，推动其盘前股价飙升逾15%。财报发布后，其股价微幅上涨。**汇丰控股 **：这家英国银行公布季度利润增长，并宣布了高达10亿美元的股票回购计划，但由于回购规模令部分投资者感到失望，其股价小幅走低。Segro股价小幅上扬，而安博盘前股价则基本持平。**辉瑞 、默沙东 、安进  与 BioNTech **：这些制药公司将在今日美股开盘前公布财报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360107168.USD","QQQA","LU1852331112.SGD","IE00BJJMRY28.SGD","LU1303367103.USD","LU0726765562.USD","BK4023","LU0980610538.SGD","CHAT","PBE","LU0133085943.USD","FHLC","LU0127658192.USD","LU1803068979.SGD","IE00BJTD4V19.USD","LEGR","LU0477156953.USD","IE00BKVL7J92.USD","LU1066051811.HKD","SG9999015358.SGD","LU2089985449.USD","BK4007","GDOC","LU0289739699.SGD","LU0238689110.USD","BK4555","PLTR","SG9999001440.SGD","JRE","LU0792757196.USD","SG9999001176.USD","BK4612","IE00BSNM7G36.USD","LU0234572021.USD","LU0256863811.USD","LU0203345920.USD","LU0417517546.SGD","BP.UK","LU1116320737.USD","GQRE","GUNZ","LU2324357040.USD","LU0965509010.AUD","LU1035773651.USD","LU1732799900.SGD","LU0648001328.SGD","LU0124676726.USD","ILDR","FAI","BK4566","LU1074936037.SGD","LU1923623000.USD","LU2461242641.AUD","LU0048584097.USD","LU1732800096.USD","BK4533","LU2860962120.EUR","IGV","LU1934455194.USD","BK4573","BK4551","BK4604","PLTU","IE0009356076.USD","LU1267930813.SGD","LU0211331839.USD","SG9999015341.SGD","LU1291159041.SGD","LU1093756325.SGD","REET","04332","BK4610","BK4504","CLIM","LU2279689827.SGD","AMDG","IBB","LU2360106780.USD","LU0689626769.HKD","ERET","IE0009355771.USD","LU2242649171.HKD","CRED","LU1244550221.USD","LU0208291251.USD","BIB","LU0198837287.USD","LU1267930227.SGD","BK4548","BK4554","RXL","BK4139","LU1917777945.USD","LU2108987350.USD","LU2265009873.SGD","LU2360032135.SGD","BK4613","ORBX","LU1244550577.SGD","MCD","LU2112291526.USD","AMDW","IYH","LU1116320901.HKD","LU0251132253.USD","IE00BJT1NW94.SGD","BBRE","IE0004445239.USD","LU1989771016.USD","LU0306806265.USD","SGXZ81514606.USD","BBH","SPRE","PSI","TRUR","SG9999002232.USD","IE00B19Z9Z06.USD","LU2458330169.SGD","LU0109394709.USD","BK4141","JDOC","AMD","IXJ","LU0225284248.USD","LU0390134368.USD","BK4512","IHE","LU1941712264.USD","TRUH","HSBC","IE00B19Z3581.USD","LU0496365809.HKD","LU1430594728.SGD","IE00BN8TJ469.HKD","LOFF","WUGI","BK4534","DTRE","LU1571399168.USD","LU2250418816.HKD","TTEQ","SCHH","PLYY","IE00BLSP4239.USD","RWO","LU1951198990.SGD","IE00B894F039.SGD","LU2290526834.HKD","SPCQ","PLTG","PTIR","DAMD","FRI","TM","SOXX","IE00B19Z9P08.USD","AMDL","LU0642271901.SGD","AMDU","LU1983299246.USD","LU0823421416.USD","LU2355687059.USD","LU0432979614.USD","LU1880398554.USD","LU2347655073.USD","BK4209","LU2491049909.HKD","BK4588","LU0861579265.USD","LU2362541513.USD","VGSR","DFAR","BK4099","TRFK","SOXY","PLTD","LU2491050154.USD","JPRE","00005","INDS","AMGN","BK4614","LU1066051498.USD","LU2125154778.USD","LU2089984988.USD","LU2931357623.SGD","LU0106261372.USD","LU2054465674.USD","AIQ","PPH","LU0976567544.SGD","TEK","LU1316542783.SGD","LU0823434740.USD","LU0795875086.SGD","RITA","BK4224","LU2596442595.SGD","LU0889565916.HKD","SPCH","LU0320765489.SGD","SSPC","SHLD","CNAV","PJP","LU1989772923.USD","SPOT","LU2361045086.USD","03160","LU1162221912.USD","BK4585","BK4529","DFGR","LU0321505439.SGD","LU0306807586.USD","LU1923622614.USD","IE00B5949003.HKD","RNTY","XLRE","IE00BZ9MQY76.HKD","LU0965509283.SGD","LU1232071149.USD","LU0098860793.USD","LU1037948897.HKD","SG9999014559.SGD","LU0965509101.SGD","LU1718418525.SGD","PLTI","BK4535","IE00BMPRXN33.USD","LU1951200564.SGD","LU1804176565.USD","IYR","RWR","LU2023250504.SGD","XNTK","LU0889566641.SGD","BAI","LU1585245621.USD","LU0719512351.SGD","LU1894683264.USD","PLTY","LU0979878070.USD","AIS","LU2491050071.SGD","PSR","LU0321505868.SGD","PFE","IE00BQXX3C00.GBP","LU0081259029.USD","SMHX","LU1861559042.SGD","SG9999001424.SGD","WISE","ICF","LU1989772840.SGD","IE00BJTD4N35.SGD","URE","LU0456855351.SGD","SG9999014575.USD","BK4516","LU0211326755.USD","LU1699723380.USD","SG9999001176.SGD","IE00BJJMRZ35.SGD","LU2133065610.SGD","BK4171","SG9999013999.USD","BK4108","SPCX","LU1066051225.USD","PPTY","CHPS","LU1861220033.SGD","LU0211326839.USD","IE00BZ1G4Q59.USD","IE00BFTCPJ56.SGD","LU0859254822.USD","REIT","LU0070302665.USD","FTXH","IE0004445015.USD","LU1242518931.SGD","LU2361044865.SGD","IE00B2B36J28.USD","LU0868494617.USD","LU2347655156.SGD","IE00BFSS7M15.SGD","LU0912757837.SGD","LU2242652126.USD","BK4521","LU0265550946.USD","GAMR","BK4207","LU1066053197.SGD","TBXU","LU2236285917.USD","IE00BQXX3F31.USD","LU1974910355.USD","SPCF","LU0823421333.USD","LU0265550359.USD","MARS","LU1037948541.HKD","SG9999002224.SGD","LU2125909593.SGD","LU1894683348.USD","AMYY","SPCG","LU0985320562.USD","LU1201861249.SGD","BK4089","IE0002270589.USD","LU0795875169.SGD","LU2462591350.SGD","SG9999014542.SGD","LU1861215975.USD","LU2361044949.HKD","LU0058720904.USD","IYRI","LU0823434583.USD","LU0823416689.USD","HRTS","LU0786609619.USD","PLD","BK4581","IE00BFSS8Q28.SGD","LU0210536198.USD","LU1934455277.USD","PLTA","LU0056508442.USD","IE00BBT3K403.USD","IE00B7KXQ091.USD","BK4568","FTXL","LU2458330243.SGD","LU0174119429.USD","LU0170899867.USD","SMH","USXF","LU1989764664.SGD","LU2264538146.SGD","LU1989764748.USD","IE00BMPRXQ63.HKD","OZEM","LU0868494708.USD","LU0203347892.USD","SG9999011175.SGD","IE00B19Z3B42.SGD","LU0052756011.USD","SG9999003800.SGD","LU0942090050.USD","IBBQ","ARTY","IE00BLSP4452.SGD","SGXZ99366536.SGD","LU2468319806.SGD","LU0130102774.USD","IE00BJJMRX11.SGD","SPAX","LU0889565833.HKD","LU1941712348.USD","LU1983260115.SGD","SPOG","LU1064131342.USD","AMDD","PLT","LU0128525689.USD","USRT","BK4550","XLV","BK4605","LU0266013472.USD","IE00B1BXHZ80.USD","LU1934455863.HKD","LU2023250843.SGD","PLOO","SGXZ51526630.SGD","LU0320765992.SGD","LU2125154935.USD","LU2106854487.HKD","LU1057294990.SGD","LU2357627491.SGD","BK4592","AIPI","LU2896262040.SGD","LU0006306889.USD","LU1244550494.USD","LU0965508806.USD","LU0122379950.USD","LU2125909247.SGD","BK4599","BK4559","VNQ","BK4543","IE0001KFT4U8.USD","IE00BQXX3D17.EUR","IETC","VHT","LU2433249047.HKD","LU1988902786.USD","LU0310800965.SGD","LU2098885051.SGD","IE00B3T34201.USD","HSBH","WARP","AVRE","LU0320765646.SGD","LU0225771236.USD","SGXZ57979304.SGD","BK4575","BK4547","BK4532","IE00BMPRXR70.SGD","LU1883839398.USD","MRK","LU1929549753.HKD","AMDS","LU0082616367.USD","WTRE","LU2247934214.USD","IE00B4R5TH58.HKD","LU1093756168.USD","IE000M9KFDE8.USD","DPRE","SPCM","LU0274383776.USD","LU0130517989.USD","LU1023059063.AUD","LU1880398471.USD","AMDY","LU0985481810.HKD","BMED","SG9999014567.USD","BK4571","IE0002141913.USD","LU2362541273.HKD","WSPC","PLTZ","LU0109392836.USD","EYES","LU2242646821.SGD","LU2362540622.SGD","BNTX","FREL","LU1861558580.USD","LU1061106388.HKD","AMUU","BK4567","PLTW","LU1069347547.HKD","PAWZ","LU1242518857.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539622","title":"非阿片止痛藥新鋭Latigo(LTGO.US)IPO擬最高募資2.88億美元，Nav1.8抑制劑劍指福泰製藥(VRTX.US)百億市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539622","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656539622?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 16:59","pubTimestamp":1785833974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2362541273.HKD","LU2468319806.SGD","IBB","IE00BFTCPJ56.SGD","LU1778281490.HKD","LU2324357040.USD","LTGO","LU1674673428.USD","LU2456880835.USD","FRHC","IBBQ","LU1093756168.USD","IE00B4R5TH58.HKD","BK4588","IE00B19Z9Z06.USD","BIB","BK4127","LU1093756325.SGD","LU0889565916.HKD","PBE","LU0234570918.USD","LU1430594728.SGD","IPOS","LU0058720904.USD","BK4585","SGXZ57979304.SGD","TBXU","KCE","IE0002141913.USD","IE00BZ9MQY76.HKD","LU0289739699.SGD","IE00B19Z9P08.USD","BBH","LU1585245621.USD","VRTX","IE00BJT1NW94.SGD","LU0256863811.USD","BK4533","LU0417517546.SGD","LU2362541513.USD","GNMX","IE00B19Z3B42.SGD","BK4532","REDS","IE00B19Z3581.USD","LU0823416689.USD","IE00BJJMRZ35.SGD","IDNA","BK4139","SG9999013999.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126575276","title":"福泰製藥重申2026年全年指引：GAAP與非GAAP研發、AI研發及銷售管理費用預期不變","url":"https://stock-news.laohu8.com/highlight/detail?id=1126575276","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126575276?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 04:07","pubTimestamp":1785787669,"startTime":"0","endTime":"0","summary":"福泰制药（Vertex Pharmaceuticals）再次确认其2026年全年财务指引。在涵盖GAAP及非GAAP口径下的研发支出、AI研发投入以及销售、一般及管理费用（SG&A）方面，该公司均维持此前预期不变，未作出任何调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4585","IDNA","LU0432979614.USD","IE0002141913.USD","LU0079474960.USD","LU0889565916.HKD","BIB","BK4532","IE00BJJMRZ35.SGD","LU0823416689.USD","LU1778281490.HKD","IE0002270589.USD","LU2362541273.HKD","LU2468319806.SGD","BK4588","LU1430594728.SGD","LU2089984988.USD","IE00BZ9MQY76.HKD","SG9999001176.SGD","VRTX","IE00B2B36J28.USD","LU0058720904.USD","LU1674673428.USD","SG9999001176.USD","SGXZ57979304.SGD","IE00B4R5TH58.HKD","LU0256863811.USD","IE00B19Z3581.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU2417539215.USD","PBE","BK4567","LU0061475181.USD","LU1093756325.SGD","LU2362540622.SGD","BK4533","LU2456880835.USD","SG9999013999.USD","LU0320765992.SGD","IBB","GNMX","IE00BJT1NW94.SGD","IE00B894F039.SGD","LU1093756168.USD","LU0417517546.SGD","BBH","LU1069344957.HKD","BK4139","LU2324357040.USD","TBXU","LU0289739699.SGD","LU2236285917.USD","LU1674673691.USD","LU1035775433.USD","IE0009355771.USD","LU0234570918.USD","LU2462157665.USD","LU2237438978.USD","IE00B19Z9P08.USD","IBBQ","LU2362541513.USD","IE00B19Z9Z06.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141963964","title":"福泰製藥：基於現行關税法規，2026年指引中關税成本影響依然微乎其微","url":"https://stock-news.laohu8.com/highlight/detail?id=1141963964","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141963964?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 04:04","pubTimestamp":1785787449,"startTime":"0","endTime":"0","summary":"福泰制药（Vertex Pharmaceuticals）表示，根据当前已知的关税税率与相关法规，其2026年业绩指引中继续纳入的关税成本影响，仍属微不足道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","LU2089984988.USD","GNMX","SG9999001176.USD","LU2362541513.USD","PBE","BBH","IE00BFTCPJ56.SGD","LU0058720904.USD","LU0256863811.USD","IE00B894F039.SGD","LU1674673428.USD","LU0289739699.SGD","LU1069344957.HKD","LU2324357040.USD","LU2417539215.USD","IE00BJJMRZ35.SGD","LU2456880835.USD","LU2468319806.SGD","IE00B19Z9P08.USD","IE0002141913.USD","IE00B2B36J28.USD","IE00B19Z9Z06.USD","BK4567","LU1585245621.USD","BK4139","LU2237438978.USD","TBXU","LU2362541273.HKD","BK4532","IE00BJT1NW94.SGD","LU1778281490.HKD","IDNA","BK4585","LU1093756168.USD","BIB","BK4588","LU0079474960.USD","LU1430594728.SGD","LU0417517546.SGD","IBBQ","LU2362540622.SGD","LU2462157665.USD","VRTX","LU0061475181.USD","LU0823416689.USD","LU1674673691.USD","LU0234570918.USD","LU0320765992.SGD","SG9999001176.SGD","IE0009355771.USD","IBB","IE0002270589.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0109394709.USD","LU1093756325.SGD","SGXZ57979304.SGD","IE00BZ9MQY76.HKD","LU0432979614.USD","BK4533","LU1035775433.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","SG9999013999.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656630972","title":"Vertex憑藉囊性纖維化藥物的強勁表現上調年度營收預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2656630972","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656630972?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 04:02","pubTimestamp":1785787378,"startTime":"0","endTime":"0","summary":"Vertex凭借囊性纤维化药物的强劲表现上调年度营收预期路透8月3日-Vertex Pharmaceuticals周一上调了年度营收预期的上限，此举得益于其囊性纤维化治疗药物需求的强劲增长。Vertex表示，其年度展望未包含待完成的Crinetics收购交易，待交易于第三季度完成后，将提供更新后的预测。该公司表示，这一增长主要得益于囊性纤维化疗法的持续良好表现。Vertex报告称，经调整后的季度每股收益为4.73美元，符合市场预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL4T4401T9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0079474960.USD","LU2362540622.SGD","LU1430594728.SGD","CRNX","IBBQ","LU2468319806.SGD","LU0256863811.USD","SG9999001176.SGD","LU1778281490.HKD","BIB","IE0009355771.USD","LU2417539215.USD","LU0432979614.USD","LU0289739699.SGD","PBE","IE0002270589.USD","LU1674673428.USD","SG9999013999.USD","LU2362541513.USD","LU0320765992.SGD","BBH","IE0002141913.USD","IE00BFTCPJ56.SGD","GNMX","LU0234570918.USD","LU1093756325.SGD","LU0417517546.SGD","TBXU","IE00B4R5TH58.HKD","IDNA","IBB","BK4567","IE00BJJMRZ35.SGD","LU2362541273.HKD","VRTX","LU1035775433.USD","LU1069344957.HKD","IE00BZ9MQY76.HKD","SGXZ57979304.SGD","BK4585","SG9999001176.USD","LU1585245621.USD","IE00B19Z9P08.USD","BK4532","LU2324357040.USD","IE00B19Z3B42.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00B894F039.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656031243","title":"加州最高法院在「創新義務」案中裁定吉利德勝訴","url":"https://stock-news.laohu8.com/highlight/detail?id=2656031243","media":"路透中文","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656031243?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 01:02","pubTimestamp":1785776562,"startTime":"0","endTime":"0","summary":"加州最高法院在“创新义务”案中裁定吉利德胜诉路透8月3日-加利福尼亚州最高法院周一就一起案件作出裁决，支持吉利德科学公司GILD.O，该案涉及被视为安全的药物制造商是否必须尝试开发更安全的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL4T4401N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加州最高法院在“创新义务”案中裁定吉利德胜诉","news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU1674673428.USD","LU1778281490.HKD","LU2089984988.USD","LU1839511570.USD","LU0965509010.AUD","LU1066051498.USD","LU0058720904.USD","BK4139","LU0823416689.USD","LU0965508806.USD","LU1057294990.SGD","LU0965509101.SGD","IBB","BK4532","IE0002270589.USD","LU1674673691.USD","LU0122379950.USD","LU2112291526.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","LU1585245621.USD","LU0882574055.USD","BK4568","SG9999015945.SGD","BMED","LU0965509283.SGD","LU1934455194.USD","TMED","IE00B3T34201.USD","IE00BSNM7G36.USD","MEDI","IBBQ","LU1037948541.HKD","BK4588","IE00BKVL7J92.USD","BBH","BK4578","IE00B19Z3581.USD","TBXU","BK4585","LU1571399168.USD","LU1037948897.HKD","IE00BZ1G4Q59.USD","GILD","LU2324357040.USD","IE00B7SZLL34.SGD","LU0861579265.USD","BIB","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187256046","title":"加州最高法院裁定吉利德科學勝訴，HIV藥物「創新責任」案塵埃落定","url":"https://stock-news.laohu8.com/highlight/detail?id=1187256046","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187256046?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 01:01","pubTimestamp":1785776475,"startTime":"0","endTime":"0","summary":"加州最高法院近期作出裁决，判定吉利德科学在一起涉及HIV药物的“创新责任”案件中胜诉。原告方曾指控吉利德，声称其明知旧款HIV药物存在肾毒性风险，却故意拖延新一代、更安全药物的研发与上市，造成了患者不必要的伤害。对于吉利德而言，这无疑是一场关键胜利，避免了潜在的巨额赔偿和声誉受损。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU1839511570.USD","LU0320765992.SGD","LU0965508806.USD","BK4578","LU1037948897.HKD","LU1778281490.HKD","LU1674673691.USD","LU0109394709.USD","BK4566","IE00B7SZLL34.SGD","LU1571399168.USD","BK4550","BK4588","LU0823416689.USD","LU1934455863.HKD","SG9999015945.SGD","LU1061106388.HKD","LU0122379950.USD","GILD","IE00BKVL7J92.USD","LU1057294990.SGD","LU1934455194.USD","IE00BZ1G4Q59.USD","IBB","LU1934455277.USD","BMED","TMED","IE00B3T34201.USD","SG9999015986.USD","LU0965509010.AUD","LU1066053197.SGD","LU2468319806.SGD","LU0058720904.USD","LU0965509101.SGD","BIB","LU0882574055.USD","IE00BSNM7G36.USD","BK4585","BK4532","BK4583","LU2324357040.USD","IE0002270589.USD","LU0861579265.USD","LU0965509283.SGD","LU0889565916.HKD","LU1674673428.USD","IE00B19Z3581.USD","BK4568","LU2112291526.USD","LU1023059063.AUD","SG9999015978.USD","TBXU","IE00B19Z3B42.SGD","IBBQ","BK4139","LU1066051498.USD","SG9999015952.SGD","LU0289739699.SGD","LU1430594728.SGD","LU2087621335.USD","MEDI","LU0234570918.USD","LU1585245621.USD","LU0114720955.EUR","LU1037948541.HKD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656134416","title":"安進7月遭網絡攻擊 部分患者信息被盜","url":"https://stock-news.laohu8.com/highlight/detail?id=2656134416","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656134416?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 10:28","pubTimestamp":1785724120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BIB","LU0058720904.USD","IE0009355771.USD","BK4533","WCBR","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU2242652126.USD","SG9999001440.SGD","BK4599","LU0109394709.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU1061106388.HKD","AMGN","BK4139","LU2242646821.SGD","BK4585","LU2112291526.USD","TBXU","IE00B2B36J28.USD","LU0122379950.USD","BK4566","IE00B4R5TH58.HKD","LU1571399168.USD","LU2468319806.SGD","PBE","SPAM","LU0320765992.SGD","HAKY","IBBQ","BK4588","LU0289739699.SGD","LU0868494617.USD","PJP","LU1023059063.AUD","UCYB","BK4581","LU1983299246.USD","IBB","BK4534","IE00BJT1NW94.SGD","IE0002141913.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":151,"code":"91000000","status":"200"}]}}